Literature DB >> 35907138

Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression.

Lihua Fu1, Dan Zhang2, Nuo Yi1, Yanjun Cao1, Yaxian Wei1, Wenjing Wang1, Li Li3.   

Abstract

Circular RNAs (circRNAs) are a class of non-coding RNAs with a unique covalently closed loop structure. Recent studies indicate that dysregulation of circRNAs acts a role in cancer progression and chemotherapy resistance via interacting with RNA-binding proteins (RBPs). Herein, we identified circPBX3 to be involved in cisplatin resistance of ovarian cancer. In our study, two cisplatin-resistant ovarian cancer cell lines were established, and transcriptome RNA-sequencing was performed and circPBX3 was identified as significantly upregulated circRNA in these cells. The characteristics of circPBX3 and potential function of circPBX3 were evaluated. We found that circPBX3 was upregulated in ovarian tumor tissues and cisplatin-resistant ovarian cancer cells. CircPBX3 overexpression increased the half maximal inhibitory rate (IC50) of cisplatin, promoted colony formation and tumor xenografts growth, and reduced cell apoptosis of ovarian cancer cells under cisplatin treatment, while silencing circPBX3 showed opposite effects. Furthermore, circPBX3 could interact with the RNA-binding protein IGF2BP2, thus increased the stability of ATP7A mRNA and elevated ATP7A protein level. In addition, silencing ATP7A in ovarian cancer cells abrogated the effect of circPBX3 overexpression on cisplatin tolerance. Our findings provided a novel role of circPBX3 in cisplatin resistance of ovarian cancer.
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.

Entities:  

Keywords:  ATP7A; Cisplatin resistance; IGF2BP2; Ovarian cancer; circPBX3

Mesh:

Substances:

Year:  2022        PMID: 35907138     DOI: 10.1007/s13577-022-00748-8

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.374


  37 in total

Review 1.  Past, present, and future of circRNAs.

Authors:  Ines Lucia Patop; Stas Wüst; Sebastian Kadener
Journal:  EMBO J       Date:  2019-07-25       Impact factor: 11.598

Review 2.  Epithelial ovarian cancer.

Authors:  Stephanie Lheureux; Charlie Gourley; Ignace Vergote; Amit M Oza
Journal:  Lancet       Date:  2019-03-23       Impact factor: 79.321

Review 3.  The Biogenesis, Functions, and Challenges of Circular RNAs.

Authors:  Xiang Li; Li Yang; Ling-Ling Chen
Journal:  Mol Cell       Date:  2018-07-26       Impact factor: 17.970

4.  Cancer statistics for adults aged 85 years and older, 2019.

Authors:  Carol E DeSantis; Kimberly D Miller; William Dale; Supriya G Mohile; Harvey J Cohen; Corinne R Leach; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-08-07       Impact factor: 508.702

Review 5.  Epithelial ovarian cancer: Evolution of management in the era of precision medicine.

Authors:  Stephanie Lheureux; Marsela Braunstein; Amit M Oza
Journal:  CA Cancer J Clin       Date:  2019-05-17       Impact factor: 508.702

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 7.  LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin.

Authors:  Mohammad Taheri; Hamed Shoorei; Farhad Tondro Anamag; Soudeh Ghafouri-Fard; Marcel E Dinger
Journal:  Exp Mol Pathol       Date:  2021-01-08       Impact factor: 3.362

8.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.

Authors:  Celeste Leigh Pearce; Claire Templeman; Mary Anne Rossing; Alice Lee; Aimee M Near; Penelope M Webb; Christina M Nagle; Jennifer A Doherty; Kara L Cushing-Haugen; Kristine G Wicklund; Jenny Chang-Claude; Rebecca Hein; Galina Lurie; Lynne R Wilkens; Michael E Carney; Marc T Goodman; Kirsten Moysich; Susanne K Kjaer; Estrid Hogdall; Allan Jensen; Ellen L Goode; Brooke L Fridley; Melissa C Larson; Joellen M Schildkraut; Rachel T Palmieri; Daniel W Cramer; Kathryn L Terry; Allison F Vitonis; Linda J Titus; Argyrios Ziogas; Wendy Brewster; Hoda Anton-Culver; Alexandra Gentry-Maharaj; Susan J Ramus; A Rebecca Anderson; Doerthe Brueggmann; Peter A Fasching; Simon A Gayther; David G Huntsman; Usha Menon; Roberta B Ness; Malcolm C Pike; Harvey Risch; Anna H Wu; Andrew Berchuck
Journal:  Lancet Oncol       Date:  2012-02-22       Impact factor: 41.316

9.  Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression.

Authors:  Shuo Chen; Wu Wu; Qian-Hui Li; Bu-Min Xie; Fan Shen; Yu-Ping Du; Zhi-Hong Zong; Li-Li Wang; Xiao-Qing Wei; Yang Zhao
Journal:  Cell Death Discov       Date:  2021-01-22

10.  CircRAB11FIP1 promoted autophagy flux of ovarian cancer through DSC1 and miR-129.

Authors:  Zhanqin Zhang; Hongtao Zhu; Jianguo Hu
Journal:  Cell Death Dis       Date:  2021-02-26       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.